Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 2/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718893 | 1.00 | MEN1 (0.46) | MEN1KMT2ANUDT1MAPK8MAPK9 | |
| SCHEMBL1938007 | 0.83 | STK17A (0.50) | MEN1KMT2ANUDT1MAPK8STK17B | |
| SCHEMBL13897499 | 0.81 | MEN1 (0.52) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL13649070 | 0.81 | KMT2A (0.41) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL4137651 | 0.80 | NUDT1 (0.51) | MEN1KMT2ANUDT1MAPK8MAPK9 | |
| SCHEMBL5436631 | 0.79 | NUDT1 (0.43) | MEN1KMT2ANUDT1MAPK8STK17B | |
| SCHEMBL13649041 | 0.78 | KMT2A (0.39) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL3447092 | 0.78 | KMT2A (0.50) | MEN1KMT2ASTK17BSTK17AALDH1A1 | |
| SCHEMBL5786509 | 0.78 | NUDT1 (0.45) | MEN1KMT2ANUDT1MAPK8MAPK9 | |
| SCHEMBL5789412 | 0.78 | NUDT1 (0.42) | MEN1KMT2ANUDT1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| CN-111808080-B | Substituted pyridine or pyrimidine compound, preparation method and medical application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112469719-B | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3797107-B1 | HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-07-08 | — | — | US | disclosed |
| EP-3797107-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2021-03-31 | — | — | EP | disclosed |
| CN-112469719-A | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-111808080-A | Substituted pyridine or pyrimidine compound, preparation method thereof and application thereof in medicine | 四川科伦博泰生物医药股份有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | MEN1 4225/4885KMT2A 4486/4885NUDT1 218/4885 |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | IDH1, IDH2, IDH3A | MEN1 1149/4885KMT2A 506/4885NUDT1 926/4885 |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | MEN1 1149/4885KMT2A 506/4885NUDT1 926/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | MEN1 4491/4885KMT2A 2879/4885NUDT1 1614/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | MEN1 4645/4885KMT2A 2709/4885NUDT1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.